Brett P. Monia, Ph.D., has been the CEO of Ionis Pharmaceuticals since January 2020. With a strong background in biotechnology, he holds a Ph.D. and has been pivotal in developing antisense-based drugs over more than three decades. Under his leadership,...

Brett P. Monia, Ph.D., has been the CEO of Ionis Pharmaceuticals since January 2020. With a strong background in biotechnology, he holds a Ph.D. and has been pivotal in developing antisense-based drugs over more than three decades. Under his leadership, Ionis continues to innovate in the biotech space, focusing on delivering medicines that tackle serious diseases. Brett has worked at Ionis in various roles since 2000, including Chief Operating Officer and Senior Vice President of Drug Discovery. He’s not only a businessman but also an inventor, holding over 100 patents and having supervised programs that led to the clinical development of more than 40 drugs. His business decisions are closely tied to performance metrics, impacting both company revenue and operational goals which are reflected in the bonuses he receives. Brett’s insider trading patterns show a significant increase in stock holdings in recent years, reflecting confidence in the company's direction. He also places strong emphasis on corporate responsibility, linking it to long-term value creation for stakeholders. Brett’s experience and dedication make him a key player in the biotechnology field.